Clinical Characteristics of Patients Who Contracted the SARS-CoV-2 Omicron Variant from an Outbreak in a Single Hospital
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
There are few studies on the severity and prognosis of patients infected with the severe acute respiratory syndrome-coronavirus-2(SARS-CoV-2) omicron variant. From January 11, 2022 to January 25, 2022, 181 patients were infected with the SARS-CoV-2 omi cron variant in a single hospital in Korea. The initial clinical characteristics were investigated through the COVID-19 basic investi gation form. Outcomes were reviewed using medical records. The median age of the patients was 57 years (range 1–90), and 95patients (52.5%) were male. None were re-infected with SARS-CoV-2, and 127 (70.2%) were fully vaccinated (boosted or within 6months after second vaccination). Forty-two patients (23.2%) were asymptomatic. Among symptomatic patients, the frequencyof symptoms was as follows: cough (37.0%), sore throat (33.7%), and fever (30.4%). In terms of disease severity, 168 (92.8%) pa tients did not require supplemental oxygen, 6 (3.3%) required low-flow oxygen, 5 (2.8%) required high-flow oxygen, and 2 (1.1%)died. Four of the five individuals who required high-flow oxygen and the two who died were not vaccinated. Most of the patientswho contracted the SARS-CoV-2 omicron variant exhibited mild clinical features; however, severe clinical features including mor tality were encountered among individuals who were not vaccinated.
Abstract
There are few studies on the severity and prognosis of patients infected with the severe acute respiratory syndrome-coronavirus-2(SARS-CoV-2) omicron variant. From January 11, 2022 to January 25, 2022, 181 patients were infected with the SARS-CoV-2 omi cron variant in a single hospital in Korea. The initial clinical characteristics were investigated through the COVID-19 basic investi gation form. Outcomes were reviewed using medical records. The median age of the patients was 57 years (range 1–90), and 95patients (52.5%) were male. None were re-infected with SARS-CoV-2, and 127 (70.2%) were fully vaccinated (boosted or within 6months after second vaccination). Forty-two patients (23.2%) were asymptomatic. Among symptomatic patients, the frequencyof symptoms was as follows: cough (37.0%), sore throat (33.7%), and fever (30.4%). In terms of disease severity, 168 (92.8%) pa tients did not require supplemental oxygen, 6 (3.3%) required low-flow oxygen, 5 (2.8%) required high-flow oxygen, and 2 (1.1%)died. Four of the five individuals who required high-flow oxygen and the two who died were not vaccinated. Most of the patientswho contracted the SARS-CoV-2 omicron variant exhibited mild clinical features; however, severe clinical features including mor tality were encountered among individuals who were not vaccinated.
참고문헌 (14)
- [URL]
- Adam D, "Will omicron end the pandemic? Here’s what experts say", Nature, 602, pp.20~21 (2022)
- Araf Y, "Omicron variant of SARS-CoV-2 : genomics, transmissibility, and responses to current COVID-19 vaccines", J Med Virol, 94, pp.1825~1832 (2022)
- Maslo C, "Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 omicron wave compared with previous waves", JAMA, 327, pp.583~584 (2022)
- WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection, "A minimal common outcome measure set for COVID-19 clinical research", Lancet Infect Dis, 20, pp.e192~e197 (2020)
- Meo SA, "Omicron SARS-CoV-2new variant : global prevalence and biological and clinical characteristics", Eur Rev Med Pharmacol Sci, 25, pp.8012~8018 (2021)
- Kim Min-Kyung, "Clinical Characteristics of 40 Patients Infected With the SARS-CoV-2 Omicron Variant in Korea", Journal of Korean Medical Science, 37(3), pp.1~5 (2022), 대한의학회[DOI]
- Ren SY, "Omicron variant (B.1.1.529)of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance", World J Clin Cases, 10, pp.1~11 (2022)
- "SARS-CoV-2 variants of concern and variants under investigation in England"[URL]
- CDC COVID-19 Response Team, "SARS-CoV-2 B.1.1.529 (omicron)variant - United States, December 1-8, 2021", MMWR Morb Mortal Wkly Rep, 70, pp.1731~1734 (2021)
- Andrews N, "COVID-19 vaccine effectiveness against the omicron(B. 1. 1. 529)variant", N Engl J Med, 386, pp.1532~1546 (2022)
- Ssentongo P, "SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19 : a systematic review and meta-analysis", BMC Infect Dis, 22, pp.439~ (2022)
- Atmar RL, "Homologous and heterologous COVID-19 booster vaccinations", N Engl J Med, 386, pp.1046~1057 (2022)
- Garcia-Beltran WF, "mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 omicron variant", Cell, 185, pp.457~466.e4 (2022)